![Crystal structure of 4-[4-(2-adamantylcarbamoyl)-5-ter-butyl-pyrazol-1-yl] benzoic acid, aka AZD8329, a type 2 diabetes drug candidate.](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tyw22_3HQUOXgfZY1_kMl4wRMO6uEjAtTNKjYsHmbrcSCEaGnNs0_RJ5d8PQmYMRtoz6XL0kayOuJAtT3g31_SVXW1wuYLmWXLdO4yK2Ptf609W4iuuLUBl95nVVqiXvt4rV3g05iEE16azGfX0rX_4YXVFTRU2g1mwu_BimbA0BycI6IoLOG9VxMLmEAIyR5TvG6l78rug84jym0XmhLtpMeiOLkuPOTdTOZ2vvRq504LG4zt=s0-d "Crystal structure of 4-[4-(2-adamantylcarbamoyl)-5-ter-butyl-pyrazol-1-yl] benzoic acid, aka AZD8329, a type 2 diabetes drug candidate.")
The crystal structure of AZD8329 form 4 was determined using solid-state NMR.
Molecules can crystallize in different forms, which may have variable stability or solubility properties. For materials and pharmaceutical applications that use microcrystalline powders, manufacturers must be able to reliably produce specific crystal forms and have analytical methods available to ensure that they’re doing so.
No comments:
Post a Comment